Chordia Therapeutics
Fujisawa, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing novel small molecule kinase inhibitors for oncology and immunology, with multiple clinical-stage assets.
OncologyImmunology
Technology Platform
Structure-based drug design platform for developing selective small molecule inhibitors targeting challenging kinases including CLK, MALT1, CDK12, and GCN2.
Opportunities
Expansion of rogocekib clinical program could demonstrate proof-of-concept for CLK inhibition, potentially attracting partnership interest.
Their academic collaboration with Kyoto University provides access to cutting-edge research on CDK12 biology.
Risk Factors
Termination of CTX-177 partnership with Ono Pharmaceutical represents a setback and highlights dependency on external partners.
Clinical validation of novel kinase targets carries significant biological and development risk.
Competitive Landscape
Competes in crowded kinase inhibitor space but differentiates through focus on less-explored targets (CLK, GCN2) and structure-based design for selectivity. Faces competition from larger pharma companies with broader kinase portfolios.